Paclitaxel-coated balloons for femoropopliteal peripheral arterial disease: final five-year results of the IN.PACT Global Study.

ABSTRACT:

Background

Numerous randomised controlled trials (RCTs) have demonstrated the superiority of paclitaxel drug-coated balloons (DCBs) over non-coated angioplasty balloons for treatment of femoropopliteal peripheral arterial disease (PAD). There is a paucity of clinical evidence in more complex patients who are often excluded from RCTs and long-term data up to 5 years are very limited in PAD revascularisation studies.

Aims

This is a report of the 5-year outcomes from the prospective, single-arm, international IN.PACT Global Study. The IN.PACT Admiral DCB was evaluated for femoropopliteal atherosclerotic disease treatment in a real-world patient population.

Methods

In total, 1,535 patients were enrolled at 64 international sites. The prespecified clinical cohort included

SUBMITTER: Zeller T 

PROVIDER: S-EPMC9743239 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature